在三线复发内对白金耐药卵巢癌患者的二次细胞减小手术的评估:多中心,随机对照研究
Tingting Chen1,2, Junfen Xu1,2, Bairong Xia3
1Department of Gynecology and Oncology, Women's Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China.
Journal of gynecologic oncology
|November 9, 2023
概括
这项临床试验调查了对抗性卵巢癌 (ROC) 的二次细胞还原手术 (SCS). 它旨在确定SCS的有效性,并确定其在复发性卵巢癌患者中使用的标准.
科学领域:
- 妇科瘤学 妇科瘤学
- 手术瘤学手术瘤学
- 临床试验 临床试验
背景情况:
- 表皮卵巢癌是妇科癌症死亡的主要原因之一.
- 的耐药性显著限制了治疗选择,并挽救了化疗的疗效.
- 二次细胞还原手术 (SCS) 正在引起人们对抗性复发性卵巢癌 (ROC) 的关注,特别是在寡度转移方面,但缺乏证据和标准化标准.
研究的目的:
- 评估SCS在ROC妇女的治疗价值.
- 澄清可靠的标准来选择有资格接受SCS的患者.
- 为了比较SCS加化疗与单独化疗在抗ROC中.
主要方法:
- 一个多中心的,随机的,受控的临床试验 (NCT05633199).
- 140名具有抗ROC的参与者满足"RSCS标准"将被随机分配1:1.
- 实验组:SCS随后进行非化疗;标准组:仅进行非化疗.
主要成果:
- 主要结局:没有进展的生存.
- 二次结果:总体存活率,不良事件和与健康有关的生活质量.
- 研究招聘于2023年1月1日开始,计划于2026年12月结束.
结论:
- 这项研究将提供关于SCS在抗ROC的疗效的证据.
- 将建立在ROC中使用SCS的可靠标准.
- 这些发现将为复发性白金耐药性卵巢癌的治疗策略提供信息.
更多相关视频
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10.5K
09:40Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
2.7K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...